Blood pressure didn’t increase in any evaluated subgroup. Christen M. Anderson, M.D., Ph.D., Arena’s Vice President of Clinical Advancement, stated, ‘The pooled Phase 3 data show that lorcaserin effectively treated a diverse populace of adult men and women who had a need to lose weight. Lorcaserin’s influence on weight loss also led to improvements in cardiovascular risk elements in all subgroups evaluated.’.. Arena’s lorcaserin reduces body weight across patient subgroups Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 sufferers in lorcaserin’s pivotal Stage 3 clinical trial system that demonstrate lorcaserin 10 mg dosed twice daily decreased body weight in every individual subgroups evaluated, as described by gender, age group, ethnicity and starting body weight and Body Mass Index .Food and Medication Administration . The novel outpatient method delivers managed thermal energy to lessen excess airway smooth muscles that is connected with airway constriction in sufferers with asthma. By reducing the power of the airways to constrict, this fresh treatment has been proven to greatly help patients with serious asthma gain considerably better control over their disease. We have been honored to become the 1st hospital offering this brand-new procedure to adults battling with serious asthma in the DC metro region, stated David R.